TW202308696A - 拓撲異構酶i抑制劑之肽結合物之給藥方案 - Google Patents

拓撲異構酶i抑制劑之肽結合物之給藥方案 Download PDF

Info

Publication number
TW202308696A
TW202308696A TW111116202A TW111116202A TW202308696A TW 202308696 A TW202308696 A TW 202308696A TW 111116202 A TW111116202 A TW 111116202A TW 111116202 A TW111116202 A TW 111116202A TW 202308696 A TW202308696 A TW 202308696A
Authority
TW
Taiwan
Prior art keywords
compound
administered
pharmaceutically acceptable
acceptable salt
days
Prior art date
Application number
TW111116202A
Other languages
English (en)
Chinese (zh)
Inventor
維斯瓦斯 帕羅卡
亞瑟 P 德克立斯
Original Assignee
美商斯布雷克薩二號公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商斯布雷克薩二號公司 filed Critical 美商斯布雷克薩二號公司
Publication of TW202308696A publication Critical patent/TW202308696A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW111116202A 2021-04-29 2022-04-28 拓撲異構酶i抑制劑之肽結合物之給藥方案 TW202308696A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163181640P 2021-04-29 2021-04-29
US63/181,640 2021-04-29

Publications (1)

Publication Number Publication Date
TW202308696A true TW202308696A (zh) 2023-03-01

Family

ID=81749580

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111116202A TW202308696A (zh) 2021-04-29 2022-04-28 拓撲異構酶i抑制劑之肽結合物之給藥方案

Country Status (12)

Country Link
US (1) US20240226308A1 (cg-RX-API-DMAC7.html)
EP (1) EP4329817A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024516825A (cg-RX-API-DMAC7.html)
KR (1) KR20240019097A (cg-RX-API-DMAC7.html)
CN (1) CN117897175A (cg-RX-API-DMAC7.html)
AU (1) AU2022267389A1 (cg-RX-API-DMAC7.html)
CA (1) CA3218253A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003187A1 (cg-RX-API-DMAC7.html)
IL (1) IL308052A (cg-RX-API-DMAC7.html)
MX (1) MX2023012779A (cg-RX-API-DMAC7.html)
TW (1) TW202308696A (cg-RX-API-DMAC7.html)
WO (1) WO2022232808A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
BR112022000297A2 (pt) 2019-07-10 2022-03-15 Cybrexa 3 Inc Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006078816A2 (en) 2005-01-18 2006-07-27 The Board Of Governors For Higher Education Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide
CA3032186C (en) 2010-07-13 2022-04-26 Council on Postsecondary Education, State of Rhode Island and Providence Plantations Environmentally sensitive composition comprising a ph triggered peptide and uses thereof
SG10201913073YA (en) * 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
AU2019205325A1 (en) 2018-01-05 2020-08-13 Cybrexa 1, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
US20210106648A1 (en) * 2019-10-11 2021-04-15 TOBEBIO Novel Drug Laboratory Co., Ltd. Synergistic combination of chemotherapy and peptide for treating cancer

Also Published As

Publication number Publication date
KR20240019097A (ko) 2024-02-14
CA3218253A1 (en) 2022-11-03
IL308052A (en) 2023-12-01
AU2022267389A9 (en) 2023-11-16
AU2022267389A1 (en) 2023-11-09
CN117897175A (zh) 2024-04-16
EP4329817A1 (en) 2024-03-06
US20240226308A1 (en) 2024-07-11
MX2023012779A (es) 2024-01-16
WO2022232808A1 (en) 2022-11-03
JP2024516825A (ja) 2024-04-17
CL2023003187A1 (es) 2024-05-03

Similar Documents

Publication Publication Date Title
WO2023107706A1 (en) Stat3 degraders and uses thereof
JP2023539715A (ja) 抗体-薬物コンジュゲートとatm阻害剤との組合わせ
TW202038957A (zh) 抗體-藥物結合物與激酶抑制劑之組合
US20240226308A1 (en) Dosing regimens of peptide conjugates of topoisomerase i inhibitors
AU2011325989C1 (en) Methods of treating cancer
EP3735267B1 (en) Adminsitration of multiple boluses of [6r] mthf in a 5-fluorouracil-based chemotherapy
AU2016309002A1 (en) Combination therapy using liposomal irinotecan and a PARP inhibitor for cancer treatment
JP6425653B2 (ja) 抗腫瘍剤及び抗腫瘍効果増強剤
KR20200096788A (ko) 화학치료법-내성 난소암 또는 유방암 치료에서 parp 억제제의 용도
US20190212341A1 (en) Methods for treating colorectal and metastatic colorectal cancers
TW201617081A (zh) 以妥布賴森(Tubulysin)結合物治療癌症之方法
CN118414173A (zh) 抗体-药物缀合物和parp1选择性抑制剂的组合
US20230116137A1 (en) Methods for treating colorectal and metastatic colorectal cancers
WO2024214685A1 (ja) 抗b7-h3抗体-薬物コンジュゲートとatr阻害剤又はatm阻害剤との組み合わせ
AU2018234141A1 (en) Combination between trifluridine/tipiracil hydrochloride, an anti-tumor platinum complex, and an immune checkpoint modulator
JP2025143272A (ja) がんを処置する方法及び使用
JP2025524343A (ja) 新規ras阻害剤
TWI528960B (zh) 用於治療增生性疾病的醫藥組合物
WO2024258916A1 (en) Stat3 degraders and uses thereof
WO2024255883A1 (zh) Akt抑制剂在制备预防或治疗乳腺癌药物中的用途
Tolcher et al. 403 POSTER Clinical responses in highly refractory solid tumor patients with oral MP-470, a multi-targeted tyrosine kinase inhibitor, in combination with standard of care chemotherapy regimens: preliminary report from a multi-institutional phase-1b clinical trial
TW202034959A (zh) 抗體-藥物結合物與parp抑制劑之組合
WO2019183385A1 (en) Mapk/erk inhibition for ovarian and other cancers
HK40040066B (en) Administration of multiple boluses of [6r] mthf in a 5-fluorouracil-based chemotherapy
HK40040066A (en) Administration of multiple boluses of [6r] mthf in a 5-fluorouracil-based chemotherapy